|
|
 |
|
|
|
|
Factoid of the Day
|
Friday, September 13, 2019
|
|
The U.S. Food and Drug Administration (FDA) has approved 27 new drugs this year (thru 9/12), down from 35 approvals at this point last year, according to its own release. The FDA approved an all-time high of 59 new drugs in 2018. Tufts Center for the Study of Drug Development estimates that drug companies, on average, endure out-of-pocket costs approaching $1.4 billion for newly developed, FDA-approved prescription medicines, according to Policy & Medicine.
|
|
ETF – Listing Date: August 20, 2019
First Trust EIP Carbon Impact ETF (ECLN)
|
| |
Unit Investment Trusts Upcoming Deposit Information |
Initial Offer Date |
| |
Click Here
for CUSIP Information.
|
| • |
Automated Quantitative Analysis, 19 |
9/16/2019 |
| • |
Core Three Closed-End Allocation, 41 |
9/16/2019 |
| • |
Municipal Income Select, Closed-End, 105 |
9/16/2019 |
| • |
Dividend Growers and Tax-Advantaged Income, 20 |
9/17/2019 |
| • |
Dow Jones Global Titans, 29 |
9/18/2019 |
| • |
International High Dividend Equity, 38 |
9/18/2019 |
| • |
Strategic Income Select Closed-End, 41 |
9/18/2019 |
| • |
Precious Metals Select, 42 |
9/19/2019 |
| • |
Sabrient Baker's Dozen, September 2019 |
9/20/2019 |
| • |
Brookmont Equity Dividend, 21 |
9/23/2019 |
| • |
Deep Value Dividend Opportunity, 10 |
9/23/2019 |
| • |
NextGen Communications and Technology, 3 |
9/23/2019 |
| • |
Senior Loan & Limited Duration Opportunities Closed-End, 64 |
9/23/2019 |
| • |
Stonebridge Preferred Income, 24 |
9/23/2019 |
| • |
Equity Closed-End, 55 |
9/25/2019 |
| • |
Global Equity Income Closed-End, 67 |
9/25/2019 |
| • |
Senior Loan & Limited Duration Closed-End, 91 |
9/25/2019 |
| • |
Emerging Markets Strength, 46 |
9/27/2019 |
| • |
Income Dividend Equity Allocation (IDEA), 22 |
9/27/2019 |
| • |
Richard Bernstein Advisors Quality Income, 35 |
9/27/2019 |
| • |
FT Equity Allocation ETF Model, 4th Qtr 2019 |
9/30/2019 |
| • |
FT High Income Model, 4th Qtr 2019 |
9/30/2019 |
| • |
Pacific Northwest, 3 |
10/2/2019 |
| • |
ETF Growth and Income, October 2019 |
10/3/2019 |
| • |
Diversified Equity Strategic Allocation, 4th Qtr 2019 |
10/9/2019 |
| • |
Dow® Target 10, October 2019 |
10/10/2019 |
| • |
Dow® Target 5, 4th Qtr 2019 |
10/10/2019 |
| • |
Dow® Target Dividend, 4th Qtr 2019 |
10/10/2019 |
| • |
European Target High Quality Dividend, 4th Qtr 2019 |
10/10/2019 |
| • |
Global Target 15, 4th Qtr 2019 |
10/10/2019 |
| • |
Income Allocation Closed-End, 4th Qtr 2019 |
10/10/2019 |
| • |
S&P Dividend Aristocrats Target 25, 4th Qtr 2019 |
10/10/2019 |
| • |
S&P Target 24, 4th Qtr 2019 |
10/10/2019 |
| • |
S&P Target SMid 60, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Diversified Dividend, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Diversified Global Allocation, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Dividend Blend, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Dividend Double Play, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Double Play, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Focus Four, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Global Dividend Leaders, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Growth, 4th Qtr 2019 |
10/10/2019 |
| • |
Target High Quality Dividend, 4th Qtr 2019 |
10/10/2019 |
| • |
Target Triad, 4th Qtr 2019 |
10/10/2019 |
| • |
Target VIP, 4th Qtr 2019 |
10/10/2019 |
| • |
Value Line® Target 25, 4th Qtr 2019 |
10/10/2019 |
| • |
Value Line® Target Safety 30, 4th Qtr 2019 |
10/10/2019 |
| • |
40/60 Strategic Allocation, 4th Qtr 2019 |
10/11/2019 |
| • |
60/40 Strategic Allocation, 4th Qtr 2019 |
10/11/2019 |
| • |
75/25 Strategic Allocation, 4th Qtr 2019 |
10/11/2019 |
| • |
Diversified Fixed Income ETF, 41 |
10/11/2019 |
|
| First Trust Mobile |
 | Get the latest First Trust product and research information on your smartphone or tablet device!
Learn more... |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial advisors are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|